Cell and Gene Therapies – Current and Future Landscape

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$5000
Buy Report Download FREE Resources

Published: November 28, 2024 Report Code: GDHCHT540-ST

Select Item

Reasons to buy the ‘Cell and Gene Therapies’ market report:

  • Design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the CGT in the Oncology, Hemophilia A & B, CNS, and ophthalmology markets.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Oncology, Hemophilia A & B, CNS, and ophthalmology-targeting CGT therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

How is our ‘Cell and Gene Therapies’ report unique from other reports in the market?

  • Get an overview of the current and future landscape of cell and gene therapies (CGT).
  • Clients can explore the therapy areas and indications set to drive rapid growth in the CGT market over the near and long term.
  • Understand the CGT marketed and pipeline landscape, with launch date projections, market size, likelihood of approval analyses, and a case study that explores the challenging pricing and reimbursement (P&R) landscape for these therapies.
  • In addition to commentary on deals, assess financials and valuations set to shape the CGT space over the coming years.

We recommend this valuable source of information to anyone involved in:

  • ​​​​Drug Development and ​​​​Pharma/Biotech Companies – Value Chain
  • Pharma/Drug Manufacturing Companies – Leaders and Startups
  • Pharmaceutical Industry Suppliers & Distributors
  • Business Development and Market Intelligence
  • Investment Analysts and Portfolio Managers
  • Professional Services – Investment Banks, PE/VC Firms
  • M&A/Investment, Management Consultants, and Consulting Firms

To Get a Snapshot of the Cell and Gene Therapies  Report

Download a Free Report Sample

Cell and Gene Therapies Market Report Overview

The market size for cell and gene therapies (CGT) is estimated to be $5.88 billion in 2023. The market will grow at a CAGR of more than 43% from 2023 to 2030. Cell therapies refer to any treatment in which cells are transplanted into a patient. This can include the patient’s cells or those of a donor (autologous versus allogeneic). Gene therapy is the introduction of exogenous genetic material into cells to treat a disease. They provide a therapeutic benefit to patients, especially those suffering from monogenic diseases.

Cell and Gene Therapies Market Outlook, 2023-2030 ($Billion)

Cell and Gene Therapies Market Outlook, 2023-2030 ($Billion)

Buy the Full Report to Know More about the Cell and Gene Therapies Market Forecast

Download a Free Sample Report

The cell and gene therapies market research report provides an overview of the current and future landscape of cell and gene therapies (CGT). This report helps the client explore the therapy areas and indications set to drive rapid growth in the CGT market over the near- and long-term. Furthermore, the report helps to gain an understanding of the CGT marketed and pipeline landscape, with launch date projections, market size, likelihood of approval analyses, and a case study that explores the challenging pricing and reimbursement (P&R) landscape for these therapies. Additionally, the report provides a commentary on deals, financials, and valuations set to shape the CGT space over the coming years.

Market Size (2023) $5.88 Billion
CAGR (2023-2030) >43%
Forecast Period 2023-2030
Key Therapy Areas ·       Oncology

·       Metabolic Disorders

·       Hematological Disorders

·       CNS Disorders

·       Ophthalmology
Key Companies ·       Johnson & Johnson

·       Legend Biotech

·       Gilead

·       Bristol Myers Squibb

·       Sarepta Therapeutics
Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

Cell and Gene Therapies Market Segmentation by Therapy Areas

The key therapy areas in the cell and gene therapies market are Oncology, Metabolic Disorders, Hematological Disorders, CNS Disorders, and Ophthalmology, among others. In 2024, oncology accounted for the highest share of the cell and gene therapies market.

Cell and Gene Therapies Market Analysis by Therapy Areas, 2024 (%)

Cell and Gene Therapies Market Analysis by Therapy Areas, 2024 (%)

Buy the Full Report to Know More about the Therapy Areas of Cell and Gene Therapies Market

Download a Free Sample Report

Cell and Gene Therapies – Competitive Landscape

A few of the leading companies in the cell and gene therapies market are:

  • Johnson & Johnson
  • Legend Biotech
  • Gilead
  • Bristol Myers Squibb
  • Sarepta Therapeutics

Cell and Gene Therapies Market Analysis by Companies, 2024

Cell and Gene Therapies Market Analysis by Companies, 2024

Buy the Full Report for More Company Insights into the Cell and Gene Therapies
Download a Free Sample Report

Johnson & Johnson
Legend Biotech Corp
Gilead Sciences Inc
Bristol-Myers Squibb Co
Sarepta Therapeutics Inc
Novartis AG
Tenaya Therapeutics Inc
CRISPR Therapeutics AG
Intellia Therapeutics Inc
Sana Biotechnology Inc
Iovance Biotherapeutics Inc
Atara Biotherapeutics Inc
Rocket Pharmaceuticals Inc
Beam Therapeutics Inc
MeiraGTx Holdings Plc
Ultragenyx Pharmaceutical Inc
Vertex Pharmaceuticals Inc
RegenxBio Inc
Allogene Therapeutics Inc
Krystal Biotech Inc
bluebird bio Inc
Pfizer Inc
CSL Behring
BioMarin Pharmaceutical Inc
Roche Holding AG
Spark Therapeutics Inc
ASC Therapeutics Inc
Expression Therapeutics Inc
BIOCAD
Vitalgen
Gene Vector Barcelona
Sichuan Real & Best Biotech Co., Ltd.
Kyowa Kirin Co Ltd
SanBio Co Ltd
CorestemChemon Inc
NIPRO CORPORATION
Holostem Srl
Aurion Biotech
FujiFilm
Japan Tissue Engineering Co., Ltd. (J-TEC)
Hirosaki Lifescience Innovation, Inc.
Reliance Life Sciences Inc
MeiraGTx
Sumitomo Pharma Co., Ltd
Kala Bio
4D Molecular Therapeutics Inc
Adverum Biotechnologies
Astellas Pharma
Lumos Pharma
Lyell Immunopharma
ImmPACT Bio
Ocuphire Pharma
Kiji Therapeutics
REGiMMUNE
Matica Bio
Nona Biosciences
OverT Bio
MiNK Therapeutics
Autonomous Therapeutics
Alpine Immune Sciences
AviadoBio
Sangamo Therapeutics
Umoja Biopharma
Ascidian Therapeutics
Voyager Therapeutics
Xyphos Biosciences
Kelonia Therapeutics
China Resources Sanjiu Medical and Pharma (CR Sanjiu)
Tasly Pharma Group
Capricor Therapeutics
Nippon Shinyaku
Kyverna Therapeutics Inc

Table of Contents

Table of Contents (PowerPoint Deck)

Preface

Contents

Abbreviations

1. Overview – Cell and Gene Therapy Landscape

1.1. CGT Landscape – Market Size

1.2. What is Cell and Gene Therapy?

1.3. CGT Landscape – Market Size by Molecule Type

1.4. CGT Landscape – Market Size by Therapy Area

1.5. CGT Landscape – Key Players (2023 Versus 2030)

1.6. CGT Landscape – Key Therapies of Top 10 Players (Prescription Sales)

2. Deep-Dive into the CGT Landscape – Oncology and Hematology

2.1. CGT in Oncology Overview

2.2. CGT in Oncology Overview – Allogeneic Versus Autologous Cell Therapies

2.3. CGT in Hematology Overview

2.4. CGT in Hematology Overview – Marketed Profiles

2.5. Hemophilia Gene Therapies Provide Unmatched Long-Term Bleed Protection Despite More Stringent Eligibility

2.6. Leading Players Have Adopted Similar Messaging and Marketing Strategies

2.7. Medical Needs in Hemophilia A and B Are Not Adequately Addressed

2.8. Major Players Intensify Hemophilia Competition Within One Year’s Time

2.9. Hemophilia CGT Segment Is Expected to Pass $2.14 Billion by 2029

2.10. Hemophilia CGT Landscape Is Mixed With Developers of Different Sizes

2.11. Key Takeaways

3. Deep-Dive into the CGT Landscape – Central Nervous System Disorders

3.1. Executive Summary

3.2. History of the Development of CGT in Central Nervous System Disorders

3.3. Marketed Product Profiles

3.4. Commercial Activities of Marketed CGTs in Central Nervous System Disorders

3.5. Challenges and Opportunities in CGT in Central Nervous System Disorders

3.6. Top 20 Central Nervous System Disorders with CGT Development

3.7. Top Five Central Nervous System Disorders with the Most CGT Pipeline Assets

3.8. Additional Players Expected to Join the Competition Within Five Years

3.9. CGT Candidates Have Lower Likelihood of Approval and Phase Transition Success Rate Versus Indication Benchmarks

3.10. Key Takeaways

4. Deep-Dive into the CGT Landscape – Ophthalmology

4.1. Executive Summary

4.2. History of the Development of CGT Therapies in Ophthalmology

4.3. Marketed Product Profiles

4.4. Commercial Activities of Marketed CGTs in Ophthalmology

4.5. Challenges and Opportunities in CGT in Ophthalmology

4.6. Top 20 Ophthalmology Indications with CGT Development

4.7. Top Five Ophthalmology Indications with the Most CGT Pipeline Assets

4.8. Additional Players Expected to Join the Competition Within Five Years

4.9. CGT Candidates Typically Have Lower LoA and PTSR Versus Indication Benchmarks

4.10. Key Takeaways

5. CGT Landscape –Pricing and Reimbursement Challenges and Access

5.1. Casgevy – The World’s First CRISPR-Based Gene Editing Therapy to be Approved

5.2. Casgevy’s Route to Patient Access – Challenges and Opportunities

5.3. France – First to Grant (Early) Patient Access to Casgevy via the Autorisation d’Accès Précoce System

5.4. UK – Interim NHS Managed Access to Casgevy via the Innovative Medicines Fund

5.5. Current Challenges in Conducting Health Technology Assessments for CGTs

5.6. Future Challenges in Conducting Health Technology Assessments for CGTs

5.7. Innovative Payment Model Types with Potential for CGTs in the Future

5.8. Key Takeaways

6. CGT Landscape – Deals, Financials, and Valuations

6.1. Deals Landscape – Mergers, Acquisitions, and Strategic Alliances of CGT by Region

6.2. Deals Landscape – Recent Mergers, Acquisitions, and Strategic Alliances in CGT for 2024

6.3. Deals Landscape – Top Mergers, Acquisitions, and Strategic Alliances in CGT for 2024

6.4. Private Companies Show Signs of Venture Financing Recovery

6.5. Downturn in CGT Investment Continues in 2024

6.6. US NIH SBIR/STTR Grant Funding Increases for CGT

6.7. Less Acquisition Spend as More Private Companies Go Public

6.8. CGT IPOs Completed in 2024, but Number Remains Low

6.9. Higher Trial Cost Estimates Remain for Gene Therapies

6.10. Average Venture Capital Deal Amount by Lead Asset’s Molecule Type ($ Million)

6.11. Oncology Remains the Top Therapy Area for Venture Financing

6.12. Key Takeaways

7. CGT Landscape – Key Takeaways

8. Appendix

8.1. Methodology – Sales Forecasts

8.2. Methodology – Phase Transition Success Rate and Likelihood of Approval Analysis

8.3. GlobalData’s Team – About the Authors

9. Contact Us

Frequently asked questions

Cell and Gene Therapies – Current and Future Landscape standard reports
Currency USD
$5,000

Can be used by individual purchaser only

Most Popular
$10,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$15,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

Cell and Gene Therapies – Current and Future Landscape was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Pharmaceuticals reports
Pharmaceuticals
New
Reflux Esophagitis (Gastroesophageal Reflux Disease): Market View, Current and Future…
$3,495 | June 2026
Pharmaceuticals
New
IgA Nephropathy (Berger’s Disease): Market View, Current and Future Competitive…
$3,495 | June 2026
Pharmaceuticals
New
Hepatocellular Carcinoma (HCC): Epidemiology Report and Forecast to 2035
$9,995 | June 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Cell and Gene Therapies – Current and Future Landscape in real time.

  • Access a live Cell and Gene Therapies – Current and Future Landscape dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more